GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Life Sciences Ltd

Sai Life Sciences Q1 FY27 Net Profit up 22% to ₹73 Cr, Revenue up 12%

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 06 Aug 2026, 11:16 PM IST  ·  BSE ID: c6a41f4f-9d8f-448f-98c9-34bdfcc8459a
View Original BSE Filing (PDF)
💡
In Simple Terms
Sai Life Sciences reported higher earnings and revenue for the latest quarter, along with expanding its research facilities.
🤖 AI Summary
  • Sai Life Sciences reported a 12% year-on-year increase in Revenue from Operations to ₹554 Cr for Q1 FY27.
  • Net Profit (PAT) for Q1 FY27 increased 22% year-on-year to ₹73 Cr from ₹60 Cr in Q1 FY26.
  • EBITDA stood at ₹148 Cr for Q1 FY27, an 18% increase from ₹125 Cr in Q1 FY26.
  • EBITDA Margin for Q1 FY27 was 27%, up from 25% in Q1 FY26, with PAT Margin at 13%.
  • A new 100,000 sq. ft. R&D facility in Hyderabad was operationalized, and EcoVadis Platinum Rating achieved.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations
554 ₹ crores
12%
EBITDA
148 ₹ crores
18%
EBITDA Margin%
27%
PAT
73 ₹ crores
22%
PAT Margin%
13%
🏢 How This Affects the Company
📈
Business Impact
The company's Revenue from Operations grew 12% year-on-year, indicating an expansion in both its CRO and CDMO businesses, with CRO specifically growing 24% year-on-year.
💰
Financial Impact
Net Profit (PAT) increased by 22% year-on-year to ₹73 Cr, and EBITDA grew by 18% year-on-year to ₹148 Cr, improving both EBITDA and PAT margins for the quarter.
⚙️
Operational Impact
Operationalizing a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad, expands the company's research and development capacity.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are indirectly affected by the company's financial performance, as reported by the increased revenue and profit figures.
🔍
Management Signal
Management emphasizes progress and momentum, with a focus on strategic engagements with large pharmaceutical companies and disciplined capital allocation.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q2 FY27 financial results — review revenue and profit trends.
Updates on new R&D facility utilization and impact on pipeline.
Details on the momentum of CRO and CDMO businesses in subsequent quarters.
LOW RISK The filing indicates growth in key financial metrics and operational expansion.
💡 Investor Takeaway
Sai Life Sciences reported Q1 FY27 Revenue from Operations of ₹554 Cr, an increase of 12% year-on-year from ₹496 Cr in Q1 FY26. Net Profit (PAT) grew 22% year-on-year to ₹73 Cr from ₹60 Cr.
⚖️ Strengths & Concerns

✅ Positives

  • Net Profit (PAT) increased by 22% year-on-year to ₹73 Cr in Q1 FY27, demonstrating growth in profitability.
  • EBITDA margin improved to 27% in Q1 FY27 from 25% in Q1 FY26, indicating operational efficiency gains.
📅 Company Track Record
In FY26, Sai Life Sciences reported a 109% increase in Net Profit (PAT) to ₹355 Cr and a 29% rise in Revenue to ₹2,192 Cr. The company's Q1 FY27 standalone profit increased 22.23% to Rs. 713.39 million, as per a previous filing on August 6, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sai Life Sciences' Revenue from Operations in Q1 FY27?
Sai Life Sciences reported Revenue from Operations of ₹554 Cr for the quarter ended 30 June 2026 (Q1 FY27), an increase of 12% from ₹496 Cr in Q1 FY26.
What was Sai Life Sciences' Net Profit (PAT) in Q1 FY27?
The Net Profit (PAT) for Sai Life Sciences in Q1 FY27 was ₹73 Cr, which is a 22% increase compared to ₹60 Cr in Q1 FY26.
What was Sai Life Sciences' EBITDA in Q1 FY27?
Sai Life Sciences' EBITDA for Q1 FY27 stood at ₹148 Cr, marking an 18% increase from ₹125 Cr reported in Q1 FY26.
Did Sai Life Sciences' operationalize new facilities in Q1 FY27?
Yes, Sai Life Sciences operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad, during Q1 FY27.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.